295 related articles for article (PubMed ID: 25031089)
1. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
[TBL] [Abstract][Full Text] [Related]
2. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
Vogel CW; Finnegan PW; Fritzinger DC
Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
[TBL] [Abstract][Full Text] [Related]
3. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
Vogel CW; Fritzinger DC
Toxicon; 2010 Dec; 56(7):1198-222. PubMed ID: 20417224
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment with Cobra venom factor alleviates acute lung injury induced by intestinal ischemia-reperfusion in rats.
Mao YF; Yu QH; Zheng XF; Liu K; Liang WQ; Wang YW; Deng XM; Jiang L
Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2207-17. PubMed ID: 23893188
[TBL] [Abstract][Full Text] [Related]
5. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
6. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
Fritzinger DC; Hew BE; Lee JQ; Newhouse J; Alam M; Ciallella JR; Bowers M; Gorsuch WB; Guikema BJ; Stahl GL; Vogel CW
Adv Exp Med Biol; 2008; 632():293-307. PubMed ID: 19025130
[TBL] [Abstract][Full Text] [Related]
7. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
[TBL] [Abstract][Full Text] [Related]
9. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration.
Fritzinger DC; Dean R; Meschter C; Wong K; Halter R; Borlak J; St John WD; Vogel CW
Adv Exp Med Biol; 2010; 703():151-62. PubMed ID: 20711713
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
[TBL] [Abstract][Full Text] [Related]
11. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
12. Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents.
Fritzinger DC
Hawaii Med J; 2005 May; 64(5):133-4, 137. PubMed ID: 15989147
[No Abstract] [Full Text] [Related]
13. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and characterization of a complement-depleting factor from king cobra, Ophiophagus hannah.
Zeng L; Sun QY; Jin Y; Zhang Y; Lee WH; Zhang Y
Toxicon; 2012 Sep; 60(3):290-301. PubMed ID: 22561424
[TBL] [Abstract][Full Text] [Related]
15. The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response.
Hundgeburth LC; Wunsch M; Rovituso D; Recks MS; Addicks K; Lehmann PV; Kuerten S
Clin Immunol; 2013 Mar; 146(3):155-64. PubMed ID: 23352967
[TBL] [Abstract][Full Text] [Related]
16. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat.
Till GO; Morganroth ML; Kunkel R; Ward PA
Am J Pathol; 1987 Oct; 129(1):44-53. PubMed ID: 3661679
[TBL] [Abstract][Full Text] [Related]
17. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
18. Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.
Cheung AK; Parker CJ; Wilcox L
Clin Exp Immunol; 1989 Nov; 78(2):299-306. PubMed ID: 12412765
[TBL] [Abstract][Full Text] [Related]
19. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment of donor with 1-deamino-8-d-arginine vasopressin could alleviate early failure of porcine xenograft in a cobra venom factor treated canine recipient.
Kang HJ; Lee G; Kim JY; Lee SH; Wi HC; Hwang PG; Chung DH; Kim YT
Eur J Cardiothorac Surg; 2005 Jul; 28(1):149-56. PubMed ID: 15982598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
